Will BMS and AZ strike gold with Amylin?
This article was originally published in Scrip
Gaining access to an effective glucagon-like peptide -1 receptor agonist (GLP-1) had been on the to-do list of AstraZeneca R&D president Dr Martin Mackay ever since he arrived at the company from Pfizer in mid-2010, so it was no surprise that AstraZeneca was in the final mix as a potential acquirer of Amylin Pharmaceuticals (scripintelligence.com, 2 July, 2012). Indeed, AstraZeneca and Bristol-Myers Squibb had been singled out by Scrip as the front runners in the race for Amylin, but what no one had expected was for the race to end in a dead heat with AstraZeneca opting to ride on the coat tails of the its US rival's acquisition of Amylin (scripintelligence,com, 27 June, 2012).
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.